Mangalam Drugs And Organics Limited — Important, 13-02-2025: Financial Result Updates

**Mangalam Drugs and Organics Limited Financial Summary:**

Consolidated income from operations for the quarter reached ₹58.71 crore, marking a growth from ₹57.33 crore in the previous quarter. Year-over-year comparison shows a slight decrease from ₹60.74 crore. This change is attributed to fluctuations in demand and operational efficiency adjustments in response to market conditions.

Net profit for the quarter stood at ₹7.29 crore, compared to ₹6.66 crore in the previous quarter, indicating improved profitability despite the revenue decline. The earnings per share (EPS) for the quarter is at ₹0.49, reflecting a solid year-to-date recovery as opposed to the loss of ₹7.07 per share from the same quarter last year.

Operational expenses totaled ₹83.99 crore, with a notable reduction in material costs by approximately 29% due to lower raw material prices and enhanced procurement strategies, showcasing effective cost management.

The balance sheet remains robust, with a healthy cash flow position supporting ongoing operations and upcoming strategic initiatives. The company retains a strong liquidity position and solid equity base.

Looking ahead, the company continues to focus on cost control and product innovation, targeting market expansion and improvement in operational efficiencies. Given these dynamics, a hold stance is suggested, as the company navigates through this transitional period with potential for recovery.